FCSC - Fibrocell's Latest Partnership Provides A Leg Up For Gene Therapy Products
Fibrocell Science (FCSC) was able to establish a partnership with privately held Castle Creek Pharmaceuticals. This partnership will help Fibrocell to advance its gene therapy product FCX-007 to treat patients with a rare life-threatening disease known as recessive dystrophic epidermolysis bullosa ((RDEB)). Both companies get something good out of the partnership and it will finally allow patients with RDEB to have a treatment option that they could greatly benefit from. The gene therapy is ready to enter a phase 3 study in Q2 of 2019, which means that Fibrocell is one step